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Background: Health-related quality of life (HRQoL) and health state utility value (HSUV) measurements are vital
components of healthcare clinical and economic evaluations. Accurate measurement of HSUV and HRQoL require
validated instruments. The 12-item Short-Form Health Survey (SF-12) is one of few instruments that can evaluate
both HRQoL and HSUV, but its validity has not been assessed in people living with HIV/AIDS (PLWHA) in east Africa,
where the burden of HIV is high.
Methods: This cross-sectional study used baseline data from a randomized trial involving PLWHA in Kenya. Data
included responses from a translated and adapted SF-12 survey as well as key demographic and clinical data.
Construct validity of the survey was examined by testing the SF-12’s ability to distinguish between groups known
in advance to have differences in their health based on their disease severity. We classified disease severity based
on established definitions from the US Center for Disease Control (CDC) and WHO, as well as a previously studied
viral load threshold. T-tests and ANOVA were used to test for differences in HRQoL and HSUV scores. Area under
the receive operator curve (AUC) was used to test the discriminative ability of the HRQoL and HSUV instruments.
Results: Differences in physical component scores met the minimum clinically important difference among
participants with more advanced HIV when defined by CD4 count (4.3 units) and WHO criteria (compared to stage
1, stages 2, 3 and 4 were 2.0, 7.2 and 9.8 units lower respectively). Mental score differences met the minimum
clinically important difference between WHO stage 1 and stage 4 patients (4.4). Differences in the HSUV were
statistically lower in more advanced HIV by all three definitions of severity. The AUC showed poor to weak
discriminatory ability in most analyses, but had fair discriminatory ability between WHO clinical stage 1 and clinical
stage 4 individuals (AUC = 0.71).
Conclusion: Our findings suggest that the Kiswahili translated and adapted version of the SF-12 could be used as
an assessment tool for physical health, mental health and HSUV for Kiswahili-speaking PLHWA.
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Measures of health-related quality of life (HRQoL) and
health state utility value (HSUV) measurements are vital
components of healthcare program and technology
evaluations. HRQoL is a multi-dimensional construct of
an individual or group’s perceived health status, while
HSUV ranks societal preferences for various states of
health [1, 2]. HRQoL is used to measured functional
changes in health as a clinical outcome of health inter-
ventions while HSUV describes the relative value that a
society places on living in this health state. Although the
two measures are related, they are theoretically distinct
in their derivation, application and interpretation. Accur-
ate measurement of HSUV and HRQoL require vali-
dated instruments. The limited number of validated
instruments in East Africa has impeded studies evaluat-
ing the health or economic impact of new treatments or
programs.
The 12-item Short-Form Health Survey (SF-12) is one
of few instruments that can be used to evaluate both
HRQoL and HSUV [3, 4]; however, it has not been vali-
dated for use in East Africa. The SF-12 measures eight
dimensions of health to derive a physical component
summary (PCS) and a mental health component sum-
mary (MCS). Further, an algorithm has been developed
that converts SF-12 survey data into the preference-
based Short Form 6D (SF-6D) score. The SF-6D pro-
vides information about the HSUV (based on the SF-12),
which can be used to calculate quality-adjusted life years
(QALY) [1]. The SF-12 and SF-6D are commonly used
to collect HRQoL and HSUV for health technology eval-
uations in resource-rich settings, but they are rarely used
in East Africa.
The SF-12 HRQoL scores provide descriptive mea-
sures of individual health, but not measures of economic
value. The SF-12 PCS and MCS scores cannot be used
directly to calculate quality-adjusted life years (QALY).
Societal preferences of various health states are needed
for cost-effectiveness evaluation of new health technolo-
gies, programs and interventions. Societal preferences of
the general UK population have been elicited for a
number of health states generated by the SF-12 using a
time-trade off method [1]. An algorithm has been created
based on these preferences to generate the SF-6D score, a
value between 0.35 and 1. The SF-6D instrument scores
are typically used directly in cost-effectiveness evaluations,
and it is one of the most widely used intruments to
estimate QALYs [1, 5].
HIV/AIDS is a progressive disease that results in a
complex array of health states ranging from asymp-
tomatic to severe opportunistic infection or HIV
wasting syndrome. Additionally, antiretroviral ther-
apy (ART) is associated with adverse events that can
impact an individuals HRQoL. Kenya is an EastAfrican nation that has been seriously impacted by
HIV with an estimated 1.5 million (1.3 million – 1.8
million) PLWHA in 2015 [6]. Because the SF-12 can
describe a large range of health states, it can be a
particularly useful tool to evaluate the health of
people living with HIV/AIDS (PLWHA) at all stages
of the disease. To date, the discriminative abilities of
the PCS, MCS and SF-6D have not been investigated
by HIV severity in East Africa. Given the two
distinct purposes of these instruments (i.e., measur-
ing health (SF-12) versus valuing health (SF-6D)), a
validation of both instruments is needed regardless
of the administration of the same questionnaire.
Since HIV/AIDS is the leading cause of death in
most East African nations [7], this validation is critic-
ally important for future use of the SF-12 to assess both
health and economic outcomes. The objective of this
study is to examine the performance of the Kiswahili-
translated and adapted SF-12 survey, and the correspond-
ing SF-6D scores, in Kenya. Particularly, the discriminative
ability will be evaluated between well-defined severity
groups in a sample of PLWHA.Methods
Study design and setting
This cross-sectional study, which took place between
May 2007 and October 2009, used data from a ran-
domized controlled trial (RCT) in Nairobi, Kenya
(N = 538) (ClinicalTrials.gov number, NCT00830622)
[8]. Baseline data were collected prior to initiating
ART or receiving the intervention. Data from partici-
pants in both trial arms were pooled to conduct these
analyses. This multi-site trial involved three HIV
clinics located in demographically and ethnographic-
ally diverse settings [8].Participants
Inclusion criteria were ART naïvety, aged 18 years or
above, access to a mobile phone, and the ability to text
message or have somebody who could text message on
their behalf. Individuals who met the inclusion criteria
and consented to participate were randomized to
either receive a cell-phone based adherence interven-
tion or standard care only. The study protocol was
approved by the University of Manitoba and Kenyatta
National Hospital ethics review boards [8]. The sample
size calculation was based on primary trial outcomes
including Viral load and adherence. While the trial
was not specifically powered to measure the secondary
HRQoL outcomes, a post-hoc sample size calculation
revealed the sample was adequate to detect the MCID
differences.
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The variables were defined at study entry, which took
place at ART initiation. Individuals had been receiving
care, but were ART naïve at the time of data collec-
tion. A translated and adapted SF-12 version one
survey was administered to participants at baseline
along with a survey that collected data on gender,
age, income and rural/urban residence. The SF-12
was administered on the same day that the WHO
stage, CD4 count and viral load measures were taken.
CD4 count was collected (FACScan, Becton Dickinson,
Sunnyvale, CA, USA) as part of routine clinical care and
viral load (Amplicor, Roche Diagnostics, Mannheim,
Germany) was assessed as part of the trial protocol [8].
Research clinicians administering the baseline survey
assessed the World Health Organization (WHO) clinical
stage of HIV infection [8].
Theoretical foundation
A longer form of the SF-12, the SF-36, has been
translated and adapted for use in 40 countries as part
of the International Quality of Life Assessment
(IQOLA) project [9]. Kiswahili, the primary language
in many East African nations, was not among the
original IQOLA project translations. However, two
subsequent studies (Wagner et al. and Wyss et al.)
translated and evaluated a Kiswahili translated SF-36
survey [10, 11]. Wagner et al. evaluated content, qual-
ity and scaling of the translated survey in a general
Kenyan population, demonstrating that the SF-36 sur-
vey performed comparably to the UK counterpart
[10]. Wyss et al. extended this work by assessing the
validity of the SF-36 using a method of known group
validation [11]. They demonstrated that the SF-36
could discriminate health status between groups with
known differences in health based on theory or
evidence. The discriminative ability of a HRQoL
survey is an important validation step to ensure the
survey can adequately capture outcomes of interest
[12]. The SF-36 is cumbersome to administer in re-
search settings, so the briefer SF-12 was created [3].
The SF-12 has been shown to retain much of the de-
scriptive ability and validity of the SF-36, but has not
been validated in East Africa.
Translation and adaptation process
An international team of healthcare professionals and
researchers translated the English SF-12 (Version 1)
into Kiswahili based on IQOLA recommendations.
The survey was reviewed by a multidisciplinary focus
group of English and Kiswahili speaking healthcare
providers and researchers for relevance, ease of
understanding, and cultural appropriateness. Where
necessary, items and response options were slightlymodified and culturally adapted to make the ques-
tionnaire relevant and appropriate for use in a Ken-
yan context. Literature reviews and expert opinion
were used to inform changes to the survey. For ex-
ample, ‘climbing stairs’ in the original SF-12 was
changed to ‘climbing a hill’, based on a previous study
using the SF-36 in Tanzania [10, 11]. After translating
the survey into Kiswahili, it was back translated into
English and assessed by a focus group of English
speaking healthcare researchers to ensure consistency.
The survey was pre-tested on a sample of 20 Kenyan
individuals and healthcare staff to evaluate cultural
appropriateness and understanding.
Validation
We investigated the construct validity of the survey using
known group validation [11]. This method involves
demonstrating that the PCS, MCS or SF-6D survey
scores are able to discriminate scores between groups
known a priori to have differences in their health sta-
tus. We used three established criteria to classify HIV
severity: CD4 cell count, viral load, and WHO clinical
stage of HIV infection.
We hypothesized that the HRQoL and HSUV would be
lower in more advanced HIV disease stages independently
of how severity was defined. Further, since HIV is pre-
dominantly a physical disease, we hypothesized physical
scores would show greater differences than mental health
scores. Our specific hypotheses were: 1. MCS, PCS and
SF-6D scores would be lower in individuals with
CD4 < 200; MCS, PCS and SF-6D scores would be lower
in individuals with viral load >55,000 copies/ml; and MCS,
PCS and SF-6D scores would be lower in individuals in
WHO stages 2, 3 & 4 compared to individuals in WHO
stage 1. Since WHO stage 1 individuals are asymptomatic,
we suspected that there would be a bigger difference in
HRQoL and HSUV between these individuals and more
symptomatic individuals [13].
Severity threshold definitions
We used the United States (US) Center for Disease
Control (CDC) severity stages, based on CD4 cell
count, as our first definition of disease severity [14].
Stage 1 includes individuals with a CD4 count ≥500
cells/mm3; stage 2 includes individuals with a CD4
count between 200 and 499 cells/mm3; and stage 3
includes individuals with CD4 count <200 cells/mm3.
The vast majority of individuals initiating ART have
CD4 near or below 350 cells/mm3, as that was the
ART treatment guidelines in Kenya at the time. Fur-
ther, presentation to care with advanced HIV care has
been defined as having a CD4 count below 200 [15].
To maintain an adequate sample in both groups, we
dichotomized individuals above and below CD4 count
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uals with advanced HIV infection to those without
advanced HIV infection.
Our second definition of severity was based on a
previous US study that used viral load threshold to
classify individuals [12]. Viral load is associated with
disease progression: an increased viral load indicates
advanced disease and predicts progression to AIDS
or death [16]. We classified individuals above or
below 55,000 copies/ml to assess differences in the
scores and draw descriptive comparisons to the
previous US sample [12].
Our third definition of severity was the WHO HIV
clinical staging system, which is based on physical
symptoms. The WHO clinical stages are particularly
useful in limited-resource settings, as CD4 cell counts
are not always available. Symptoms have been grouped
into four stages. Stage one individuals are asymptom-
atic; stage two individuals have mild symptoms such
as rash or upper respiratory tract infections; stage 3
individuals have moderate to severe symptoms such as
unexplained chronic diarrhea for greater than 1 month;
and stage 4 individuals have severe to life-threatening
symptoms such as extreme weight loss or opportunistic
infections.
Based on our three definitions of severity, we cate-
gorized our sample into two groups based on their
CD4 count or viral load threshold and four groups
according to WHO clinical stages. We assessed the
PCS, MCS and SF-6D, compared scores between each
groups, and determined the discriminative ability of
the scores.
Statistical analysis
We conducted a descriptive analysis of the baseline
characteristics of the study population, and stratified
the results by the severity groups we defined. We
calculated individual PCS and MCS scores using cor-
related weights from the US and SF-6D scores based
on UK weights [1, 3, 17, 18]. The SF-12 was designed
to give a population mean MCS and PCS of 50 with a
standard deviation of 10 in a disease-free US popula-
tion [3]. The minimum clinically significant difference
(MCID) for both PCS and MCS scores has been sug-
gested to be in the range 3–5 points; however, MCID
for HRQoL scores are not well-established [19]. We
used a change of 3 to interpret the clinical significance
of differences that we observed, but caution is sug-
gested in interpreting the MCID since a 1-point
change can be meaningful if it came at no additional
cost [19]. The MCID for the SF6D has been suggested
to be 0.033 (95% CI 0.029 to 0.037) [20].
We calculated mean PCS, MCS and SF-6D scores in
each of the severity categories. For CD4 and viral loadthreshold analyses, t-tests were used to test for statistical
differences between the two groups. For the WHO clin-
ical stage analysis, we used analysis of variance analysis
(ANOVA) with a post-hoc analysis to test for differences
in scores between the four groups. Participants with
missing CD4 counts, viral load or WHO stage were
excluded from the respective analysis.
We used receiver operator characteristic (ROC)
curves as a second test of the discriminative ability of
the instruments [12, 21]. Traditionally, a ROC plots
the sensitivity by 1-specificity of a diagnostic test and
helps to determine the ability of the test to discrimin-
ate between a diseased and non-diseased population.
It has also previously been used to determine the
construct validity of an instrument by evaluating if
the instrument can correctly discriminate two groups
known to have differing HRQOL [12]. We used ROC
curves to assess whether the scores could correctly
categorize a participant into a severity group using
different threshold scores as cut-offs. The area under
the ROC curve (AUC) is a measure of signal to noise
of an instrument [21]. An AUC of 1 indicates perfect
discriminatory ability; an AUC of between 0.8 to 1
shows good to excellent ability to discriminate; an
AUC of between 0.7 to 0.8 shows fair discriminative
ability; an AUC of between 0.60 and 0.70 shows weak
ability to discriminate; an AUC below 0.60 indicates a
failure to discriminate between groups; and an AUC
of 0.50 suggests the instrument is no more useful to
predict the group to which an individual belongs than
flipping a coin [21].Results
The sample had 538 participants, with greater representa-
tion by females (n = 350/538; 65%) and urban residents
(n = 436/538, 81%). Table 1 shows the characteristics of
our sample separated by severity category. CD4 count data
were complete; however, 9 (1.7%) participants had missing
SF-12 responses; 43 (8.0%) were missing viral load data;
and 72 (13.3%) were missing WHO clinical stage. Table 2
summarizes the mean scores by severity group and
Table 3 lists the AUC results of each score. We ob-
served statistically and clinically significant differences
in PCS scores in several comparisons. The MCS had a
weak signal in some comparisons, indicating that had a
modest ability to discriminate across groups. The SF-6D
scores also show monotonic trends in the hypothesized
direction in all analyses and there were statistically signifi-
cant differences in several comparisons (Table 2).Results by CD4 count threshold severity definition
Mean PCS and SF-6D scores were significantly lower in in-
dividuals with CD4 < 200 cells/mm3 than in individuals
Table 1 Characteristics of sample separated by severity category
CD4 < 200
N = 364
N (%)
CD4 ≥ 200
N = 169
N (%)
VLa >55,000
N = 281
N (%)
VLa ≤55,000
N = 214
N (%)
Stage 1
N = 114
N (%)
Stage 2
N = 126
N (%)
Stage 3
N = 204
N (%)
Stage 4
N = 22
N (%)
Male Gender 136 (37) 51 (30) 114 (41) 62 (29) 30 (26) 48 (38) 72 (35) 7 (32)
Age
20–29 62 (17) 37 (22) 46 (16) 43 (20) 30 (26) 19 (15) 39 (19) 4(18)
30–39 184 (51) 88 (52) 148 (53) 104 (49) 63 (55) 59 (47) 95 (47) 10 (45)
40–49 89 (24) 32 (19) 68 (24) 48 (22) 16 (14) 24 (19) 51 (25) 8 (36)
50+ 30 (8) 12 (7) 19 (7) 19 (9) 5 (4) 3 (2) 19 (9) 0 (0)
Income (Schillings)
≤ 2000 93 (29) 43 (29) 58 (23) 65 (35) 26 (27) 29 (25) 57 (32) 6 (30)
2001–10,000 140 (43) 71 (48) 114 (45) 80 (43) 41 (43) 59 (51) 84 (48) 4 (20)
10,001–40,000 75 (23) 30 (20) 64 (25) 36 (19) 25 (26) 24 (20) 27 (15) 10 (50)
> 40,000 14 (4) 5 (3) 15 (6) 4 (2) 3 (3) 3 (2) 8 (5) 0 (0)
Urban Res. 295 (81) 139 (82) 238 (85) 170 (79) 107 (94) 116 (92) 137 (67) 18 (82)
aVL viral load
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SF6D was 0.05 units lower suggesting a clinically significant
difference based on the MCID. The mean MCS score was
2.4 units lower in individuals with CD4 < 200 cells/mm3, so
the difference was not clinically significant. We also com-
pared mean values of PCS and MCS scores to a US sample
and scores from of our sample were comparable to the pre-
viously reported estimates (Table 4) [12]. The AUC for all
three scores were in the weak to poor range (Figs. 1 and 2),
indicating that they had some ability to distinguish these se-
verity groups (0.57–0.61). Floor and ceiling effects were ob-
served for the SF6D scores, but not for the PCS and MCS
scores (Fig. 3).
Results by viral load threshold
The SF-6D score was statistically significantly lower in
individuals with a viral load >55,000 copies/ml and met
the MCID difference we specified. The PCS and MCSTable 2 Mean HRQoL scores by severity subgroup
Sub Group PCS (SDa) MCS (SDa) SF6D (SDa)
CD4 < 200 N = 364 41.1 (11.0)* 43.4 (10.7)* 0.67(0.15)*
CD4 ≥ 200 N = 169 45.4 (10.3)* 45.8 (11.0)* 0.72(0.15)*
Viral Load >55,000 N = 281 41.5 (10.6)* 43.8 (10.9) 0.67 (0.15)*
Viral Load ≤55,000 N = 214 43.7 (11.3)* 44.5 (10.8) 0.71 (0.16)*
WHO Stage 1 N = 114 46.7 (8.7)** 46.0 (11.0)** 0.73 (0.15)**
WHO Stage 2 N = 126 44.7 (10.3) 44.6 (10.3) 0.71 (0.15)
WHO Stage 3 N = 204 39.5 (11.3)** 42.7 (11.0) 0.66 (0.16)**
WHO Stage 4 N = 22 36.9 (11.3)** 41.6 (10.2)** 0.61 (0.13)**
aStandard Deviation
*Statistically significant difference between severity group p < 0.05
**Statistically significant difference between severity group p < 0.05 based on
ANOVA with post-hoc Tukey’s procedurescores were also lower, but were not clinically significant
according to the MCID we specified. The average scores
within these viral load categories were comparable to a
previously reported US sample (Table 4). The AUC was
poor, indicating that the survey could not discriminate
well between these populations (Figs. 1 and 2).
Results by WHO stage
Both the PCS and SF-6D had a statistically significant
monotonic downwards trend as severity increased. The
difference in PCS scores between stage 1 and stages 2, 3
and 4 was 2.0, 7.2 and 9.8 units respectively, indicating a
clinically significant difference in physical health as HIV
progresses from stage 1 through 4. The AUC of the PCS
and SF-6D were 0.71 and 0.68, respectively, indicating that
the scores had fair discriminate ability between WHO
stages one and four (Fig. 1). The MCS means were statisti-
cally different between Stage 1 and Stage 4 patients and
the AUC by this comparison was 0.71 suggesting ability to
discriminate between these two groups.
Discussion
Our study shows that HRQoL and HSUV scores de-
rived from a Kenyan modified and translated SF-12Table 3 Area under the ROC curve comparisons
Comparison Groups PCS AUC MCS AUC SF6D AUC
CD4 < 200 vs CD4 ≥ 200 0.61 0.61 0.61
Viral Load ≤55,000 vs >55,000 0.56 0.54 0.57
WHO stage 1 vs stage 2 0.55 0.58 0.55
WHO stage 1 vs stage 3 0.67 0.67 0.64
WHO stage 1 vs stage 4 0.72 0.71 0.68
Table 4 Comparison of mean scores to a US sample of HIV patients
PCS Kenya Mean (SDa) MCS Kenya Mean (SD) PCS USA [11] Mean (SD) MCS USA [11] Mean (SD)
CD4 ≥ 200 cells/mm3 45.4 (10.3) 45.8 (11.0) 45.3(11.3) 42.6 (9.6)
CD4 < 200 cells/mm3 41.1 (11.0) 43.4 (10.7) 40.1 (11.4) 43.3(9.8)
Viral load ≤55,000 copies/ml 43.7 (11.3) 44.5 (10.8) 44.5 (11.6) 42.9 (9.5)
Viral load >55,000 copies/ml 41.5 (10.6) 43.8 (10.9) 40.2 (11.5) 41.6 (10.2)
aStandard Deviation
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three severity definitions. These findings suggest con-
struct validity of the modified SF-12 and may have im-
portant implications for the use of the instrument in
Kenya and other east African nations. We confirm
that the SF-12 may be used as a tool to measure phys-
ical and mental health as part of program and inter-
vention evaluations. Furthermore, the SF-12 survey
can be scored to derive an SF-6D preference-based
measure that can be used to calculate QALYs. The SF-
6D scores declined with increased severity of disease
and could theoretically rank health states in a valid
order in practice. These instruments could be particu-
larly important to support the increasing demand for
measurement and evaluation of HIV/AIDS programs.
Additionally, our results have described the mean and
distribution of HRQoL or HSUV scores for a variety of
HIV health states, and the results could be used in
mathematical models to calculate QALYs, estimate
disease burden and/or conduct economic evaluations
in Kenya.
The WHO stages were perhaps the most accurate
indication of HRQoL since the system relies on theFig. 1 The PCS and SF-6D ROC curves when comparing WHO stage one to
(AUC) is a measure of signal to noise of an instrument. The signal appears
increases. This indicates discriminatory ability of both survey scores and giv
it was designed to measurepresent or absence of a variety of symptoms based on
HIV severity. Data were collected by highly trained
research nurses as part of an internationally funded
randomized trial adding a level of scrutiny to data
collection and accuracy of classification. As would be
expected, we observed the largest differences in PCS,
MCS and SF-6D between WHO stage 1 and stage 4.
We were unable to find a similar comparison in the
literature, but the findings confirm the survey’s ability
to discriminate between groups known to have differ-
ences in HRQoL. We also observed differences in
groups by established CD4 and viral load thresholds.
We were able to confirm the survey scores could
discriminate between these alternate classifications as
further confirmation of the discriminatory ability of
the survey scores. Our findings were strengthened
through the consistent findings across multiple cri-
teria of HIV severity.
Our results were consistent with previous studies of
HRQoL and HSUV in PLWHA. Delate et al. reported
mean SF-12 summary scores in a sample of US
PLWHA [12]. The mean PCS and MCS scores we ob-
served in a Kenyan population have mostly similarmore advanced stages. Caption: The area under the ROC curve
to improve as the severity gap between the comparison groups
es face validity to them since the survey is correctly measuring what
Fig. 2 The ROC curves of SF-12 derived PCS and MCS using CD4 and viral load thresholds. Caption: The signal was weaker in this comparison,
partly because of the more general definitions of severity. However, both PCS and MCS showed some signal by CD4 severity
threshold comparison
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systematic review of HIV/AIDS focused HSUV studies,
Tengs et al. pooled utility values for three HIV health
states: asymptomatic HIV; symptomatic HIV; and
AIDS; they reported HSUVs of 0.94, 0.82 and 0.70
respectively [13]. The mean HSUVs in our sample
were generally lower (0.61–0.73) than those reported
in the systematic review (Table 2). However, the re-
view summarized evidence of HSUV of a broad sample
of PLWHA, while we assessed a cohort at a particu-
larly vulnerable time: ART initiation. Within severitygroups, the average HSUV may have improved over
time due to adaptation to disease and due to drug
treatment [22].
There were several limitations to this study. First,
normative data from the United States was used to
calculate the PCS and MCS and scoring data from the
UK was used to calculate the SF6D scores. External
scoring was used due to a lack of a local scoring algo-
rithm for the SF-12 or SF6D in Kenya or a similar set-
ting. Previous studies in Africa have used scoring data
from other settings as a surrogate to overcome this
Fig. 3 Histogram of survey scores. Caption: The PCS and MCS scores did not appear to have any floor or ceiling effects in this sample. However,
the SF6D may have had both a floor effect at a score of 0.3 and a ceiling effect at a score of 1
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ate these important measures in Kenya and other
African settings [23, 24]. Second, we were missing
WHO stage and viral load data for several partici-
pants. We had an adequate sample size to show statis-
tically significant differences between groups; however,
the direction of the potential bias due to missing data
is uncertain. Since the missing data may have been
due to administrative errors, there would likely be no
systematic pattern in missing individuals. Finally, the
survey had been modified from its original questions, so
theoretical constructs may have been affected. The survey
appears to perform as designed in main scores derived
from the survey, but more nuanced measures of health
status were not assessed in this study.
Conclusion
We found that a Kiswahili translated and adapted SF-12
survey could discriminate between HIV severity groups
in Kenya. The SF-12 is widely used in clinical trials in
the US and Europe as an objective measure of HRQoL
associated with new drug therapies and health interven-
tions. The SF-12 could accompany clinical trials being
conducted in Kenya and in other areas in East Africa to
help quantify HRQoL and HSUV that have previously
gone unmeasured. Further research is needed to show
the ability of the SF-12 survey to detect changes in qual-
ity of life over time as individuals’ health status changes.
Further research is also needed to determine Kenyaspecific scoring for both the SF-12 and SF-6D instru-
ments, and to test the survey in a broad range of diseases.
This study is a fundamental step towards increased use of
the SF-12 and other HRQoL instruments in east Africa.
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